专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07973147B2 K04-0144 substance and a process for production thereof 有权
标题翻译： K04-0144物质及其生产方法
公开(公告)号：US07973147B2
公开(公告)日：2011-07-05
申请号：US12084878
申请日：2006-05-16
申请人： Satoshi Omura , Hiroshi Tomoda , Yong-pil Kim , Hideaki Hanaki , Atsuko Matsumoto , Yoko Takahashi
发明人： Satoshi Omura , Hiroshi Tomoda , Yong-pil Kim , Hideaki Hanaki , Atsuko Matsumoto , Yoko Takahashi
IPC分类号： C07H15/20 , C07H15/22 , C07C61/12
CPC分类号： C07H11/04 , C07C323/59 , C12P13/02 , C12P19/26 , C12P19/44 , C12R1/465
摘要： A microorganism represented by a strain K04-0144 belonging to Streptomyces sp. having ability to produce K04-0144 substance is cultured in the medium, and the isolated K04-0144A substance, K04-0144B substance and K04-0144C substance therefrom have strong antibacterial activities against Gram-positive bacteria including methicillin-resistant Streptococcus aureus (MRSA), consequently these are useful as the therapeutic agents for infectious disease caused by MRSA as well as infectious diseases caused by multidrug including β-lactam antibiotics resistant bacteria. Further, similarly, since the novel K04-0144D substance isolated from the cultured liquid has the action for enhancing the effect of β-lactam antibiotics, which are utilized as the antibacterial agents, in combination with them, it is useful as the therapeutic agent for infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug including β-lactam antibiotics resistant bacteria.
摘要翻译：属于Streptomyces sp。的菌株K04-0144所代表的微生物在培养基中培养生产K04-0144物质的能力，分离的K04-0144A物质，K04-0144B物质和K04-0144C物质对革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌（MRSA））具有很强的抗菌活性，因此，这些可用作由MRSA引起的感染性疾病的治疗剂以及由多种药物（包括β-内酰胺抗生素抗性细菌）引起的感染性疾病。此外，类似地，由于从培养液中分离的新型K04-0144D物质具有增强作为抗菌剂的β-内酰胺抗生素与其组合的作用，因此可用作治疗剂用于由耐甲氧西林金黄色葡萄球菌（MRSA）引起的感染性疾病和包含β-内酰胺抗生素抗性细菌的多药物。

2. 发明申请

US20090130717A1 Novel K04-0144 Substance and a Process for Production Thereof 有权
标题翻译：新型K04-0144物质及其生产工艺
公开(公告)号：US20090130717A1
公开(公告)日：2009-05-21
申请号：US12084878
申请日：2006-05-16
申请人： Satoshi Omura , Hiroshi Tomoda , Yong-pil Kim , Hideaki Hanaki , Atsuko Matsumoto , Yoko Takahashi
发明人： Satoshi Omura , Hiroshi Tomoda , Yong-pil Kim , Hideaki Hanaki , Atsuko Matsumoto , Yoko Takahashi
IPC分类号： C12P19/44 , C07H15/10 , C12P13/02 , C12N1/20 , C07C59/62
CPC分类号： C07H11/04 , C07C323/59 , C12P13/02 , C12P19/26 , C12P19/44 , C12R1/465
摘要： A microorganism represented by a strain K04-0144 belonging to Streptomyces sp. having ability to produce K04-0144 substance is cultured in the medium, and the isolated K04-0144A substance, K04-0144B substance and K04-0144C substance therefrom have strong antibacterial activities against Gram-positive bacteria including methicillin-resistant Streptococcus aureus (MRSA), consequently these are useful as the therapeutic agents for infectious disease caused by MRSA as well as infectious diseases caused by multidrug including β-lactam antibiotics resistant bacteria. Further, similarly, since the novel K04-0144D substance isolated from the cultured liquid has the action for enhancing the effect of β-lactam antibiotics, which are utilized as the antibacterial agents, in combination with them, it is useful as the therapeutic agent for infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug including β-lactam antibiotics resistant bacteria.
摘要翻译：属于Streptomyces sp。的菌株K04-0144所代表的微生物在培养基中培养生产K04-0144物质的能力，分离的K04-0144A物质，K04-0144B物质和K04-0144C物质对革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌（MRSA））具有很强的抗菌活性，因此，这些可用作由MRSA引起的感染性疾病的治疗剂以及由多种药物（包括β-内酰胺抗生素抗性细菌）引起的感染性疾病。此外，类似地，由于从培养液体中分离的新型K04-0144D物质具有增强作为抗菌剂的β-内酰胺抗生素与其组合的作用，因此可用作治疗剂由耐甲氧西林金黄色葡萄球菌（MRSA）引起的感染性疾病和包括β-内酰胺抗生素抗性细菌在内的多种药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式